Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RGNX 
Regenxbio Inc (RGNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: RGNX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $31.75
1 Year Target Price $31.75
| 6 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.15% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 440.40M USD | Price to earnings Ratio - | 1Y Target Price 31.75 |
Price to earnings Ratio - | 1Y Target Price 31.75 | ||
Volume (30-day avg) 12 | Beta 1.09 | 52 Weeks Range 5.04 - 15.36 | Updated Date 07/9/2025 |
52 Weeks Range 5.04 - 15.36 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -100.62% | Operating Margin (TTM) 13.62% |
Management Effectiveness
Return on Assets (TTM) -17.56% | Return on Equity (TTM) -47.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 252376176 | Price to Sales(TTM) 2.81 |
Enterprise Value 252376176 | Price to Sales(TTM) 2.81 | ||
Enterprise Value to Revenue 1.61 | Enterprise Value to EBITDA -3.37 | Shares Outstanding 50388700 | Shares Floating 41110421 |
Shares Outstanding 50388700 | Shares Floating 41110421 | ||
Percent Insiders 7.7 | Percent Institutions 87.65 |
Upturn AI SWOT
Regenxbio Inc
Company Overview
History and Background
REGENXBIO Inc. was founded in 2009, focusing on developing gene therapies using its NAV Technology Platform. It has since grown through partnerships and clinical trials.
Core Business Areas
- Gene Therapy: REGENXBIO focuses on developing gene therapies for a variety of diseases, leveraging its adeno-associated virus (AAV) based NAV Technology Platform.
- Licensing NAV Technology: The company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies.
Leadership and Structure
Kenneth T. Mills is the President and CEO. The company has a typical corporate structure with executive leadership and various operational departments.
Top Products and Market Share
Key Offerings
- RGX-314: RGX-314 is being developed for the treatment of wet age-related macular degeneration (wet AMD). Competition includes Eylea and Lucentis. No market share data available directly. Revenue generated through clinical trials and potential future sales.
- NAV Technology Platform: REGENXBIO's NAV Technology Platform is a key asset, licensed to various companies for developing gene therapies. Revenue is derived from licensing agreements, with no specific market share data available.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advances in technology and increasing investment. It is characterized by intense research and development and high regulatory hurdles.
Positioning
REGENXBIO is a key player in the AAV gene therapy field with its NAV Technology Platform. It competes with other gene therapy companies and larger pharmaceutical companies.
Total Addressable Market (TAM)
The gene therapy market is projected to reach hundreds of billions USD. REGENXBIO is positioned to capture a portion of this through its pipeline and technology platform.
Upturn SWOT Analysis
Strengths
- NAV Technology Platform
- Strong intellectual property position
- Experienced management team
- Established partnerships
Weaknesses
- Limited number of commercialized products
- Dependence on partnerships for revenue
- High R&D expenses
- Clinical trial risks
Opportunities
- Expanding gene therapy market
- Potential for new licensing agreements
- Positive clinical trial results
- FDA approvals
Threats
- Regulatory hurdles
- Competition from other gene therapy companies
- Patent challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- SPHR
- VRTX
- BLUE
Competitive Landscape
REGENXBIO's NAV Technology Platform is a key competitive advantage. Competition is intense, and success depends on clinical trial outcomes.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by licensing agreements and clinical trial progress.
Future Projections: Analyst estimates vary and are subject to change. Consult financial analysts for projections.
Recent Initiatives: Recent initiatives include advancing clinical trials for RGX-314 and expanding the NAV Technology Platform applications.
Summary
Regenxbio is a gene therapy company leveraging its NAV Technology Platform. Its strengths lie in its technology and partnerships, but its weaknesses include reliance on clinical trial success and partnerships for revenue. Future growth depends on clinical trial outcomes and securing licensing agreements. Success hinges on managing regulatory and competitive pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- REGENXBIO Investor Relations
- Financial News Outlets
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary. Financial data should be verified with official sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Regenxbio Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2015-09-17 | President, CEO & Director Mr. Curran M. Simpson M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 353 | Website https://www.regenxbio.com |
Full time employees 353 | Website https://www.regenxbio.com | ||
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.